Cogent Biosciences, Inc. (NASDAQ:COGT) is certainly one of Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Inventory Picks with Enormous Upside Potential.
Cogent Biosciences, Inc. (NASDAQ:COGT) is a comparatively current addition to the 13F portfolio of Duquesne Capital. The fund first disclosed a stake within the firm within the third quarter of 2025. This place comprised simply over one million shares. Filings for the fourth quarter of 2025 present that the fund has greater than doubled this holding, upping it to greater than 2.2 million shares. Cogent is a clinical-stage biotechnology agency targeted on growing precision therapies for genetically outlined ailments. A lead product candidate for the agency consists of bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Section 3 trial designed to focus on mutations throughout the KIT receptor tyrosine kinase.
Hedge funds are betting on a valuation re-rating of Cogent Biosciences, Inc. (NASDAQ:COGT) inventory in mild of three vital regulatory milestones that the corporate has achieved. On March 16, 2026, the FDA formally accepted the New Drug Software (NDA) for bezuclastinib primarily based on the pivotal SUMMIT trial. On April 1, Cogent submitted a second NDA for GIST beneath the FDA’s Actual-Time Oncology Evaluate (RTOR) program, which considerably accelerates the approval timeline. The FDA granted this standing in late January 2026, signaling that bezuclastinib is considered as a doubtlessly superior therapy to present requirements of care. Institutional traders are targeted on the deepening scientific profit revealed within the 48-week information from the SUMMIT trial, launched Feb 2026. Sufferers noticed a 56% relative enchancment in signs, with 86% of sufferers hitting clinically significant benchmarks.
Whereas we acknowledge the potential of COGT as an funding, we imagine sure AI shares provide better upside potential and carry much less draw back threat. When you’re on the lookout for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 12 Greatest Shares to Purchase In line with Billionaire David Abrams and 15 Greatest Shares to Purchase In line with Billionaire Seth Klarman.
Disclosure: None. Comply with Insider Monkey on Google Information.